週三，CVS Health公司（NYSE:CVS）發佈了其第四季度財報。銷售額達到977.1億美元，高於市場預期的971.9億美元。
總營收同比增長4.2%，主要得益於醫療保健福利和藥房及消費健康部門的增長，儘管健康服務部門有所下降。
每股收益（EPS）經調整後爲1.19美元，較去年同期的2.12美元有所下降，但高於市場預期的0.93美元。下降的主要原因是醫療保健福利部門的經營結果減弱，包括持續的使用壓力以及2024年支付年度聯邦醫療保險星級評級的不利影響。
CVS Health還提供了對2025財年的樂觀指導，預計調整後每股收益在5.75至6.00美元之間，市場預期爲5.96美元。報告發布後，CVS在當日盤前交易中上漲了9.89%，至60.44美元。
以上內容來自Benzinga Earnings專欄，原文如下：
On Wednesday, CVS Health Corp (NYSE:CVS) reported fourth-quarter sales of $97.71 billion, beating the consensus of $97.19 billion.
Total revenues increased 4.2%, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments, partially offset by a decline in the Health Services segment.
Also Read: CVS Health Stock Is Relatively Cheap, Analyst Highlights Cost Trend Pressure Ahead Of Q4 Earnings
Adjusted EPS of $1.19 decreased from $2.12 in the prior year, beating the consensus of $0.93, primarily due to a decline in the Health Care Benefits segment's operating results, which reflect continued utilization pressure and the unfavorable impact of the Company's Medicare Advantage star ratings for the 2024 payment year.
Adjusted operating income decreased 35.5% to $2.73 billion.
Also Read: FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs
Revenues in the Health Care Benefits segment increased 23.3% to $32.96 billion, primarily driven by growth in the Medicare and individual exchange product lines.
The Medical benefit ratio increased from 88.5% to 94.8% compared to the prior year, driven by increased utilization, the unfavorable impact of the previously disclosed decline in the company's Medicare Advantage star ratings for the 2024 payment year, and the impact of higher acuity in Medicaid.
Medical membership as of December 31, 2024, of 27.1 million, increased by 1.4 million members compared with December 31, 2023, reflecting increases in the Medicare and individual exchange product lines.
Health Services segment (offering pharmacy benefit management) sales decreased 4.3% to $47.02 billion, primarily driven by the previously announced loss of a large client and continued pharmacy client price improvements. These decreases were partially offset by the pharmacy drug mix, increased contributions from the company's healthcare delivery assets, and growth in specialty pharmacy.
Pharmacy & Consumer Wellness segment sales increased 7.5% to $33.51 billion, primarily driven by pharmacy drug mix and increased prescription volume.
Prescriptions filled increased by 3.3%, and Same-store prescription volume increased by 5.9% in the quarter.
Guidance: CVS Health forecasts fiscal year 2025 adjusted EPS of $5.75-$6.00 versus consensus of $5.96.
The company expects GAAP EPS of $4.58 to $4.83, with cash flow from operations guidance of approximately $6.5 billion.
In the last 12 months, CVS stock has fallen by 29%. The stock has jumped today on positive Q4 report.
Price Action: CVS stock is up 9.89% at $60.44 during the premarket session on last check Wednesday
Read Next:
Photo: Around the World Photos via Shutterstock
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。